Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Merck Buys Plant For Follow-On Drugs
by Michael McCoy
February 16, 2009
| A version of this story appeared in
Volume 87, Issue 7
Merck & Co. will pay $130 million to acquire Insmed's portfolio of "follow-on" biologic therapeutic candidates and the firm's manufacturing facilities in Boulder, Colo. In December 2008, Merck launched a business in such follow-ons, which are therapeutically equivalent versions of currently marketed biologics. Frank K. Clyburn, general manager of Merck BioVentures, says the deal "presents the opportunity to expedite Merck's entry into the biologics marketplace." Insmed says it will use the proceeds to develop its Iplex treatment for neuromuscular and metabolic disorders.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter